NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
NCT ID: NCT05540288
Last Updated: 2025-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
266 participants
INTERVENTIONAL
2023-03-31
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many similarities have been highlighted between BAs, as well as with substance use disorders. One core clinical similarity between those disorders is craving (uncontrollable urge to engage in rewarding behaviours), which has been consistently associated with diminished control over the behaviour and relapse.
At present, no pharmacological treatment has been approved for BAs, but several medications have been tested. Among them, two opioid receptor antagonists - naltrexone and nalmefene - appear the most promising. By decreasing dopamine neurotransmission in the reward circuitry, they reduce both excitement for rewarding behaviours and craving.
Compared to naltrexone, nalmefene seems to have a better safety. To date, no study investigated the efficacy of nalmefene as a pan-addiction treatment for BAs. Two clinical trials have demonstrated its efficacy for the treatment of GD, but no clinical trial was conducted for FA and SA.
The investigators hypothesise that nalmefene (36 mg/d), compared to a placebo, can have a therapeutic effect as an add-on to usual treatment for decreasing craving in several BAs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
NCT00811941
Efficacy of Nalmefene in Patients With Alcohol Dependence
NCT00812461
Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects
NCT03034408
Efficacy of Nalmefene in Patients With Alcohol Dependence
NCT00811720
Investigation of Naltrexone for Pathological Gambling
NCT01057862
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nalmefene
Nalmefene
Week 1: 18 mg/d
Week 2:
1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d
2. In the presence of grade 3 ARs, 18 mg/d
3. In the presence of grade 4 ARs, treatment will be stopped immediately.
Week 3 to week 5:
1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage
2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.
3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage
4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d
5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Placebo
Placebo
Week 1: 1 tablet/d
Week 2:
1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d
2. In the presence of grade 3 ARs, 1 tablet/d
3. In the presence of grade 4 ARs, the treatment will be stopped immediately.
Week 3 to week 5:
1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage
2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.
3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage
4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d
5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nalmefene
Week 1: 18 mg/d
Week 2:
1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d
2. In the presence of grade 3 ARs, 18 mg/d
3. In the presence of grade 4 ARs, treatment will be stopped immediately.
Week 3 to week 5:
1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage
2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.
3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage
4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d
5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Placebo
Week 1: 1 tablet/d
Week 2:
1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d
2. In the presence of grade 3 ARs, 1 tablet/d
3. In the presence of grade 4 ARs, the treatment will be stopped immediately.
Week 3 to week 5:
1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage
2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.
3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage
4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d
5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient already in care or newly initiating care in Addictology departments for a beharioural addiction, diagnosed with current:
* Gambling disorder \[NORC DSM Screen for Gambling Problems (NODS), revised for DSM-5\]
* Food addiction \[Yale Food Addiction Scale (YFAS), revised for DSM-5\]
* Or Sexual addiction \[interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al. (2012): NODS-SA\]
* Able to regularly assess and report their craving episodes on a weekly diary
* Who provide their written informed consent
* Affiliated with French social security system or beneficiary from such system
* Having presented at least one episode of craving with an intensity ≥ 4/10 at the NRS during the week prior to inclusion
Women must meet one of the following criteria at the time of inclusion:
* use adequate contraceptive measures as recommended by the CTFG (Recommendations related to contraception and pregnancy testing in clinical trials v1.1), and have a negative pregnancy test (urine test) prior to receiving the first dose of study drug;
* or be post-menopausal (over 50 years of age with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal therapy)
* or (if under 50 years of age) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal therapy and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels
* or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).
Exclusion Criteria
* Presenting a contraindication for the use of nalmefene (listed in the SmPC):
* Known hypersensitivity to the active substance or to any of the excipients. In particular, intolerance to galactose or deficiency in Lapp lactase or glucose-galactose malabsorption (rare hereditary diseases);
* Treatment by opioid agonists (full or partial) (opioid pain relievers, opioid substitution drugs);
* Recent history of opioid dependence or current opioid dependence;
* Current symptoms of the acute opioid withdrawal syndrome;
* Suspected recent consumption of opioid (necessity to consider the half-life);
* Severe hepatic impairment (Child-Pugh stage B or C);
* Severe renal impairment (estimated glomerular filtration rate \[TFGe\] \<30 mL/min/1.73 m2);
* History of recent acute alcohol withdrawal syndrome (including hallucinations, convulsions and delirium tremens).
* Predictable opioid treatment during the study period;
* Unstable psychiatric disorders (meaning disorders for which the treatment was modified since less than a month (corresponding to the instauration of a new treatment, or the increase in dosage of a treatment already being taken)), including severe risk of suicide (i.e. necessity to engage specific medication or hospitalization; psychotropic medication engaged since less than 1 month; absence of improvement after one month of medication) (because nalmefene has not been studied in patients with unstable psychiatric disorders). Patients with a food addiction diagnosed with eating disorders marked by the presence of binge eating can be included;
* Anorexia nervosa-restricting type (because food addiction concept is poorly established among patients with AN-R, who do not have binge eating episodes induced by craving);
* Extreme leanness (body mass index \< 16.5) (because loss of appetite and/or weight loss are frequent adverse effects of nalmefene);
* Current treatment with potent inhibitor drugs of the UGT2B7 (UDP-Glucuronosyltransferase-2B7); for example: diclofenac, fluconazole, medroxyprogesterone acetate, meclofenamic acid;
* Current treatment with UGT inducing drugs; for example: dexamethasone, phenobarbital, rifampicin, omeprazole;
* Inability to indicate the time of day of the most intense craving episode (because this information will determine the time of day the treatment should be taken);
* Pregnancy (attested by a pregnancy urinary test for women of childbearing age) or breastfeeding woman;
* Trusteeship;
* Major cognitive impairment;
* Not fluent in French;
* Participation to another interventional study during the last month or expected participation to another interventional study during participation to the NABAB study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie GRALL-BRONNEC
Role: PRINCIPAL_INVESTIGATOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Besançon
Besançon, , France
CHU de Bordeaux
Bordeaux, , France
CHRU de Brest
Brest, , France
CHU de Clermont Ferrand
Clermont-Ferrand, , France
CHU de Dijon
Dijon, , France
CH de La Rochelle
La Rochelle, , France
Hospices Civils de Lyon
Lyon, , France
CHU de Montpellier
Montpellier, , France
CHU de Nantes
Nantes, , France
CHU de Nîmes
Nîmes, , France
Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
CHRU de Tours
Tours, , France
Hôpital Paul Brousse
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC21_0336
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.